Related Experiment Video
Updated: Mar 13, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
Published on: December 30, 2025
DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway
Alejandro Parrales1, Atul Ranjan1, Swathi V Iyer1
1Department of Cancer Biology, University of Kansas Medical Center, Kansas City, Kansas 66160, USA.
Abstract:
Stabilization of mutant p53 (mutp53) in tumours greatly contributes to malignant progression. However, little is known about the underlying mechanisms and therapeutic approaches to destabilize mutp53. Here, through high-throughput screening we identify statins, cholesterol-lowering drugs, as degradation inducers for conformational or misfolded p53 mutants with minimal effects on wild-type p53 (wtp53) and DNA contact mutants. Statins preferentially suppress mutp53-expressing cancer cell growth. Specific reduction of mevalonate-5-phosphate by statins or mevalonate kinase knockdown induces CHIP ubiquitin ligase-mediated nuclear export, ubiquitylation, and degradation of mutp53 by impairing interaction of mutp53 with DNAJA1, a Hsp40 family member. Knockdown of DNAJA1 also induces CHIP-mediated mutp53 degradation, while its overexpression antagonizes statin-induced mutp53 degradation. Our study reveals that DNAJA1 controls the fate of misfolded mutp53, provides insights into potential strategies to deplete mutp53 through the mevalonate pathway-DNAJA1 axis, and highlights the significance of p53 status in impacting statins' efficacy on cancer therapy.
Insights
Statins degrade mutant p53 (mutp53) by disrupting its interaction with DNAJA1, offering a new therapeutic strategy. This cholesterol-lowering drug approach selectively targets cancer cells expressing mutp53.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Mutant p53 (mutp53) stabilization promotes tumor malignancy.
- Mechanisms and therapies to destabilize mutp53 remain largely unexplored.
Purpose of the Study:
- To identify therapeutic agents that destabilize mutp53.
- To elucidate the molecular mechanisms underlying mutp53 degradation.
Main Methods:
- High-throughput screening to identify mutp53 degradation inducers.
- Investigating the role of the mevalonate pathway and DNAJA1 in mutp53 regulation.
- Utilizing gene knockdown and overexpression techniques.
Main Results:
- Statins identified as potent inducers of mutp53 degradation, with minimal impact on wild-type p53.
- Statins preferentially inhibit growth of mutp53-expressing cancer cells.
- Mevalonate pathway modulation and DNAJA1 knockdown promote CHIP-mediated mutp53 degradation.
Conclusions:
- Statins represent a promising therapeutic strategy for targeting mutp53-driven cancers.
- The mevalonate pathway-DNAJA1 axis is crucial for controlling mutp53 stability.
- p53 status is a key determinant of statin efficacy in cancer therapy.
Related Concept Videos
Abnormal Proliferation
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Negative Regulator Molecules
The Unfolded Protein Response
DNA Damage can Stall the Cell Cycle

